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Abstract 
Background: Methylene blue (MB) possesses all the required properties for the clinical 
management of COVID-19. We have coined methylene blue as an anti-hypoxemia and 
anti-respiratory distress agent and previously witnessed promising results in phase 1 & 
2 clinical trials. 
Methods: In the phase 3 clinical trial, the efficacy of MB has been evaluated as an 
adjunct therapy along with standard care protocols in the treatment of COVID-19 
patients. A randomized, controlled, open-label clinical trial was conducted from 20 
September through to 20 November 2020, and two hundred twenty-three hospitalized 
patients with confirmed severe cases of COVID-19 were recruited. Patients were 
randomly assigned to receive either oral MB (the reduced form: 1mg/kg T.I.D. for 2-
days, followed by 1mg/kg B.I.D. for the next 12 days) along with standard care (MB-
group: 106) or standard care alone (SC-group: 117). The outcomes were duration of 
hospital stay and mortality. 
Results: The hospital stay, measured in days, was significantly shortened in the MB-
group (6.2 ± 3.1) in comparison to the SC-group (10.6 ± 9.2, p<0.001), and a marginal 
significant decrease in mortality was seen in the MB-group (12.2%) in comparison to 
SC-group (21.4%, p= 0.07). 
Conclusions: We conclude that MB, as an adjunct therapy, can be used along with 
standard care protocols for the treatment of COVID-19. Larger studies in other centers 
are needed to confirm these findings. MB is a low-cost and FDA-approved drug for 
methemoglobinemia. 
 
Keywords: COVID-19; Treatment; Methylene Blue; Mortality 
 
Corresponding Author:  
Dr. Daryoush Hamidi Alamdari, Surgical Oncology Research Center, Mashhad 
University of Medical Sciences, Mashhad, Iran. Telephone number: 00989151017650 
email: Hamidiad@mums.ac.ir 





In the clinical management of COVID-
19 patients, oxygen support, anti-viral 
agents, antibiotics, anticoagulants, 
immunomodulatory drugs, antioxidants 
and fluid therapy are applied (Shenoy et 
al, 2020; Perkinset al, 2020). Methylene 
blue (MB) possesses all the required 
medicinal characteristics along with 
anti-hypoxemia and anti-respiratory 
properties, making it a candidate drug 
for the treatment of COVID-19 
(Alamdari et al, 2020;, Alamdari et al, 
2020, Alamdari et al, 2021). 
In our phase 1 (Alamdari et al, 2020) 
and 2 (Alamdari et al, 2021) clinical 
trials, we determined the effectiveness 
of MB in the treatment of COVID-19 
patients and coined MB as an anti-
hypoxemia drug (reduced MB converts 
Fe3+ in methemoglobin to Fe2+ so that 
the oxygen bound to Fe2+ and can be 
transported) and an anti-respiratory 
distress agent (McPherson, 2017). The 
addition of MB to the treatment 
protocols for severe COVID-19 patients 
was associated with significant clinical 
benefits which resulted in decreased 
duration of hospital stay and mortality 
(Alamdari et al, 2021).  
In continuation of our clinical trials, 
phase 3 clinical trial was designed to 
verify the efficacy of MB (the reduced 
form) for treating hospitalized patients 
with severe COVID-19 by determining 





This study was performed at Mashhad 
University of Medical Sciences, 
Mashhad, Iran, after ethics committee 
approval (IR.MUMS.REC.1399.122; 
IRCT20191228045924N120, 
September 20, 2020; ClinicalTrials.gov 
Identifier: NCT04370288; April 19, 
2020) and taking written informed 
consent from patients. Enrollment for 
the clinical trial began on September 20, 
2020, and ended on November 20, 
2020. The authors were responsible for 
designing the trial and for collecting 
and analyzing the data. The clinical trial 
has been conducted according to the 




This study was a randomized, 
controlled, parallel, open-label trial. 
The authors could not perform the study 
blind because of the blue discoloration 
of the urine in the intervention group. 
Neither the statistician, nor 
investigators, nor patients were masked 
to the treatment assignment. No drugs 
were masked and a placebo was not 
used. Inclusion criteria were severe 
patients with age above 18 years, 
respiratory distress (≧26 breaths/min), 
oxygen saturation ≤93% at rest in the 
room air, a confirmed case of COVID-
19 (by RT-PCR on the collected 
nasopharyngeal swab or clinical and 
typical HRCT features). Exclusion 
criteria were a history of G6PD 
deficiency, severe renal failure, 
cirrhosis, active chronic hepatitis, a 
history of an allergic reaction to MB, 
treatment with immunosuppressive 
agents, pregnancy, breastfeeding, and 
the presence of any condition that 
would not allow the protocol to be 
followed safely such as cognitive 
impairments or poor mental status. 
Eligible patients were randomly 
assigned to either the MB-group (106 
patients) or the SC-group (117 
patients).  
 
Methylene blue syrup formulation 
The compositions of the syrup were 
MB, vitamin C, dextrose, N-acetyl 
cysteine. The special formulation for 
MB (the reduced form) was patented 
according to the pathology of COVID-
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19 disease (IR-139950140003002083) 
(on June 1, 2020, PCT). 
 
Intervention 
For the MB-group, along with standard 
care, MB syrup was administered orally 
to patients (1 mg/kg every 8 hours for 
two days, followed by 1 mg/kg every 12 
hours for the next 12 days). For the SC-
group, the standard care protocol was 
continued.  
The standard care protocols were 
applied according to WHO guidelines. 
In the standard care protocols, severe 
patients receive supplemental oxygen, 
antiviral agents, intravenous fluids, 
antibiotics, anticoagulants, 
corticosteroids (Smith et al, 2020; 
Janssen et al, 2020).  Antivirals: 
Remdesivir (200 mg on the first day and 
100 mg for 4 days), and IFN-β 
(44µg/sc, daily for 3 doses); antibiotics: 
Azithromycin (500mg/day, 5 days), 
Meropenem (1 gr, TDS, 7-10 days), 
Ceftriaxone (1 gr, BID, 7 days), and 
Vancomycin (1 gr, BID, 7-10 days); 
and corticosteroids: Dexamethasone (8 
mg/day for 10 days), anticoagulants (up 
to discharge). 
The measured outcomes were duration 
of hospital stay and mortality rate 
within 28 days. It should be noted that 
hospital stay was counted from the day 
following MB treatment. 
 
Analysis 
Continuous variables were compared 
by the t-test and Mann-Whitney test 
based on data distribution. The paired t-
test was used to compare the mean 
difference of these variables (hospital 
stay and mortality rate) in each study 
group. The significance level was less 
than 0.05 in all statistical analyses. 








Demographic characterizations of 
patients in the MB-group and the SC-
group are presented in Table 1. 
Comorbidities in both group were 
hypertension, cardiovascular disease, 
diabetes, malignancy, cerebrovascular 
disease, asthma and chronic obstructive 
pulmonary disease (COPD). 
 
Table 1: Demographic and clinical 
characteristics of SC-group and MB-
group. 
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After MB therapy, the hospital stay 
(days) was significantly shortened in 
the MB-group (6.2 ± 3.1) in comparison 
to the SC-group (10.6 ± 9.2, p<0.001) 
and a marginal significant decrease of 
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mortality was seen in the MB-group 
(12.2%) in comparison to SC-group 
(21.4%, p= 0.07). No serious adverse 
effects were observed in the MB-group 
except the color of patients' urine turned 
to green or blue. 
 
Discussion 
This trial showed that MB, as a 
supplementary therapy to the standard 
care protocols, leads to significant 
decrease of hospital stay and mortality 
rate. 
Severe COVID-19 patients presented 
with a chief complaint of dyspnea. After 
1 day of MB administration, 90 percent 
of patients expressed dyspnea relief. 
This finding was very important for the 
care of COVID-19 patients suffering 
from respiratory distress. 
In our previous trials, we explained in 
detail, the biochemical processes in the 
pathogenesis of the disease (Alamdari 
et al, 2020, Alamdari et al, 2021).  
The rationale for considering MB for 
treatment was due the following 
mechanisms: 1) Anti-viral activity 
against the SARS-CoV-2 virus 
(Bojadzic et al, 2020; Kovács, 1960; 
Chan et al, 2011), 2) Anti-hypoxemia 
activity by converting iron from the 
ferric (Fe3+) state to the ferrous (Fe2+) 
state (an approved medicine for 
methemoglobinemia) (Smith et al, 
2020), 3) Anti-respiratory distress 
activity (Alamdari et al, 2020), 4) 
Inhibitor of nitrite production (nitrite 
converts ferrous iron to ferric iron in 
hemoglobin) by inhibiting nitric oxide 
synthase and guanylate cyclase in 
activated macrophages (Mayer et al, 
1993), 5) Antimicrobial agent (Woo 
and Heil, 2017), 6) Inhibitor of reactive 
oxygen species (superoxide anion and 
hydrogen peroxide scavenger) (Riedel 
et al, 2003), 7) Inhibitor of xanthine 
oxidase (which produces superoxide 
anion) (Salaris et al, 1991), 8) Anti-
platelet aggregation drug (Miclescu and 
Wiklund, 2010), 9) Antifungal agent 
(Haynes et al, 2010), 10) Anti-
inflammatory agent  (Lin et al,2017). 
 
Conclusion  
MB therapy along with standard care 
could be very efficacious in the 
treatment of COVID-19. Since MB is 
an inexpensive, ubiquitously 
accessible, and FDA-approved drug for 
methemoglobinemia, this drug is an 
excellent supplementary choice for the 
treatment of hypoxemia in COVID-19 
patients. We suggest that the golden 
time of MB administration should be 
upon diagnosis and at least before the 
severe stage of the disease, where 
patients present with multi-organ 
involvement and failure. MB can 
significantly reduce hospital stay and 
mortality. 
 
Limitation of the Study 
Limitations were the conducting of the 
trial in one university center with a 
small number of patients. 
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